Tower Research Capital LLC TRC Increases Stake in Vaxcyte Inc.

Summary

Tower Research Capital LLC TRC significantly increased its holdings in Vaxcyte, Inc. (NASDAQ: PCVX) during the fourth quarter, with a growth of 1,376.1%, purchasing an additional 13,458 shares, totaling 14,436 shares valued at $1.18 million. Other institutional investors also adjusted their holdings. Analysts have repeatedly given Vaxcyte’s stock a buy rating with an average target price of $136.50. The company reported quarterly earnings per share of ($1.02), exceeding expectations, and is focused on developing vaccines for bacterial infectious diseases.Market Beat

Impact Analysis

The event is classified at the company level, focusing on Vaxcyte, Inc. The significant increase in holdings by Tower Research Capital LLC signals strong investor confidence and a positive outlook for Vaxcyte’s future performance. Analysts have provided multiple buy ratings for Vaxcyte, suggesting favorable market sentiment and potential share price growth. The average target price of $136.50 implies a substantial upside from recent closing prices, presenting an investment opportunity for investors seeking growth in the biotechnology sector. Vaxcyte’s focus on developing vaccines for bacterial infectious diseases could drive future revenue growth and enhance its competitive position in the market.Market Beat+ 3